WO2003033739A1 - Compositions et procedes utilises en tant que support solide afin de purifier de l'arn - Google Patents

Compositions et procedes utilises en tant que support solide afin de purifier de l'arn Download PDF

Info

Publication number
WO2003033739A1
WO2003033739A1 PCT/US2001/032073 US0132073W WO03033739A1 WO 2003033739 A1 WO2003033739 A1 WO 2003033739A1 US 0132073 W US0132073 W US 0132073W WO 03033739 A1 WO03033739 A1 WO 03033739A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
solid support
solution
biological material
group
Prior art date
Application number
PCT/US2001/032073
Other languages
English (en)
Inventor
Ellen M. Heath
John M. Wages, Jr.
Original Assignee
Gentra Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentra Systems, Inc. filed Critical Gentra Systems, Inc.
Priority to AU2002211719A priority Critical patent/AU2002211719B2/en
Priority to EP01979794A priority patent/EP1438426A1/fr
Priority to CA002463317A priority patent/CA2463317A1/fr
Priority to JP2003536461A priority patent/JP3979996B2/ja
Priority to PCT/US2001/032073 priority patent/WO2003033739A1/fr
Publication of WO2003033739A1 publication Critical patent/WO2003033739A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes

Definitions

  • Nucleic acids such as deoxyribonucleic acid (DNA) and ribonucleic acid
  • RNA are used extensively in the field of molecular biology for research and clinical analyses. RNA may be found in nature in various forms which include messenger
  • RNA mRNA
  • tRNA transfer RNA
  • rRNA ribosomal RNA
  • viral RNA each of which have distinct properties related to their specific functions. Analysis of RNA expression levels and patterns provides important information in fields such as developmental genetics, drug discovery and clinical diagnostics. For example, RNA analysis provides important diagnostic information about both normal and aberrant functioning of genes. Furthermore, gross DNA rearrangements associated with common leukemias are detected by isolation and identification of abnormal, hybrid RNAs.
  • RNA common methods for analyzing RNA include northern blotting, ribonuclease protection assays (RPAs), reverse transcriptase- polymerase chain reaction (RT-PCR), cDNA preparation for cloning, in vitro translation and microarray analyses. To obtain valid and consistent results from these analyses, it is important that the RNA be purified from other components common to biological materials such as proteins, carbohydrates, lipids and DNA.
  • RPAs ribonuclease protection assays
  • RT-PCR reverse transcriptase- polymerase chain reaction
  • cDNA preparation for cloning in vitro translation and microarray analyses.
  • RNA purification methods fall into two general categories, liquid phase and solid phase purification.
  • liquid phase purification the RNA remains in the liquid phase while impurities are removed by processes such as precipitation and/or centrifugation.
  • solid phase purification the RNA is bound to a solid support while impurities such as DNA, proteins, and phospholipids are selectively eluted.
  • Both purification strategies utilize conventional methods, which require numerous steps and, often, hazardous reagents, as well as more rapid methods, which require fewer steps and usually less hazardous reagents.
  • the starting biological material comprises cells
  • both methods require a cell or viral co-rupture or lysis step that results in a mixture of RNA with contaminants such as DNA, lipids, carbohydrates, proteins, etc.
  • Such mixtures also contain RNases which easily degrade RNA and must be removed and/or inactivated.
  • liquid phase RNA isolation methods have used liquid-liquid extraction (i.e, phenol-chloroform) and alcohol precipitation.
  • liquid-liquid extraction method is the "acid-guanidinium-phenol” method of Chomczynski and Sacchi (Chomczynski P, Sacchi N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal Biochem 162: 156-9 [1987]; US Patent Nos. 5,945,515, 5,346,994, and 4,843,155).
  • This method comprises: (1) extracting the sample with a guanidinium isothiocyanate (GITC) solution to which an acidic medium, phenol, and chloroform are added consecutively; (2) centrifuging the mixture to separate the phases such that the proteins denatured by the phenol may be removed from the nucleic acids which are found in an intermediate layer; (3) adding an alcohol so as to precipitate and thereby concentrate the RNA; and (4) washing and re-hydrating the purified RNA.
  • GITC guanidinium isothiocyanate
  • This method ensures the purification of RNA, it utilizes hazardous reagents such as chloroform and phenol.
  • Precipitation of nucleic acids by cationic detergents is another example of liquid phase technology (U.S. Patent Nos.
  • U.S. Patent No. 5,985,572 discloses a novel method for isolating RNA from biological samples using selected quaternary amine surfactants.
  • a non-hazardous liquid phase purification method was disclosed by Heath (U.S. Patent 5,973,137) using low pH lysing and precipitation reagents.
  • liquid phase methods have serious disadvantages in that they involve tedious precipitation steps, and are consequently difficult to automate.
  • solid phase methods As with liquid phase purification, conventional solid phase methods have been developed to generate highly purified RNA.
  • these methods require four general steps: lysing cells or viral coats to release RNA; binding the released RNA to a solid support; washing away impurities; and then eluting the purified RNA.
  • the first two steps, lysing the cells or viral coats and binding the released RNA, have traditionally required hazardous reagents.
  • Solid phase methods can be classified broadly according to the type of solid phase used for such extractions, either silica or ion-exchange resins.
  • many solid supports have been used including membrane filters, magnetic beads, metal oxides, and latex particles.
  • Probably the most widely used solid supports are silica-based particles (see, e.g., U.S. Pat. No. 5,234,809 (Boom et al.); International Publication No. WO 95/01359 (Colpan et ⁇ /.);U.S. Pat. No. 5,405,951 (Woodard); International Publication No. WO 95/02049 (Jones); WO 92/07863 (Qiagen GmbH).
  • Nucleic acids bind to silica in the presence of chaotropic agents.
  • a high concentration chaotropic solution such as guanidine thiocyanate to bind DNA to silica particles and requires six centrifugation steps and five reagents to purify DNA from whole blood.
  • Boom teaches (1) mixing the biological material with a solution consisting of guanidine thiocyanate, EDTA and Triton X-100, and silica; (2) allowing the nucleic acid to bind to the silica; (3) washing the silica with consecutive washes of guanidine thiocyanate, ethanol, acetone; and (4) eluting the nucleic acid with an eluent.
  • Disadvantages of this method are the use of a particulate suspension, the use of many centrifugation steps, and the use of hazardous reagents, such as guanidine isothiocyanate and acetone.
  • the long-chain nucleic acids must be eluted at high salt concentrations for an ion-exchange method to work.
  • Commonly used salts e.g., NaCl and KC1
  • ion-exchange isolation of nucleic acids requires a final desalting step.
  • Polycationic solid supports have also been used in the purification of nucleic acids from solutions containing contaminants. See U.S. Patent No. 5,599,667 (Arnold et al.) Polycationic supports selectively adsorb nucleotide multimers based on their size, the larger multimers having a higher affinity for the polycationic support than the smaller ones. This method is based largely on the affinity between positively charged cationic solid supports and negatively charged phosphate backbones of nucleotides. Larger nucleotide multimers have higher charges and will consequently bind preferentially over smaller nucleotide multimers.
  • the method of Arnold is suited to the isolation of nucleotide multimers based on size rather than the isolation of all types of RNA from crude biological materials. Furthermore, the method of Arnold limits itself to the use of polycationic supports composed of cations such as ammonium, immonium and guanidinium ions.
  • a recent purification method employs the principle that RNA precipitates preferentially in the presence of guanidinium salts under defined buffer conditions. See U.S. Patent No. 5,972,613 (Somack et al.). In this method, RNA is precipitated in the presence of guanidinium salts at low temperatures, while the DNA remains in solution. Yet another method employs this principle, with the added presence of lithium salts. See U.S. Patent No.
  • the biological material is lysed in an acidic solution containing a lithium salt and a chaotropic agent such as guanidinium isothiocyanate (GITC), after which the RNA is brought into contact with a nucleic acid-binding carrier such as silica.
  • a chaotropic agent such as guanidinium isothiocyanate (GITC)
  • GITC guanidinium isothiocyanate
  • the RNA is subsequently purified by eluting from the silica in a low ionic-strength buffer.
  • this method is disadvantageous in its use of hazardous substances such as the chaotropic salt, guanidine thiocyanate.
  • chaotropic substances such as guanidine thiocyanate, guanidine hydrochloride, sodium iodide, and lithium chloride/urea mixtures at ionic strengths greater than 4 M in conjunction with silica-based carriers have been taught by Hillebrand et al. See WO 95/34569. However, this invention is limited to a one- step method involving a slurry of silica beads to which the aforementioned chaotropic substances are added.
  • RNA purification strategies there is a need for solid phase RNA purification strategies.
  • reagents and methods that are adaptable to solid phase purification strategies which are not only simple and rapid, but general in scope to maximize adaptability for automation.
  • reagents that are stable at room temperature (i.e., 20-25°C), less hazardous (i.e., less corrosive or toxic), nonparticulate to eliminate the need for mixing, and protective of RNA quality.
  • methods with few steps that can be performed using a variety of biological starting materials, whether hydrated or dried, especially as applied to routine testing as found in clinical and research laboratories.
  • RNA purification reagents must not inhibit subsequent RNA analysis procedures by carrying over particulates or interfering with the buffering capacity or ionic conditions of downstream analyses such as: reverse transcriptase reactions, amplification reactions, nuclease protection assays, northern blotting, and microarray and other labeling reactions.
  • the present invention provides reagents, methods, and kits that incorporate a solid support for isolating substantially pure and undegraded RNA from liquid and dried biological samples.
  • the purified RNA is suitable for use in widely used analytical and diagnostic methods such as RT-PCR and microarray analyses that require substantially pure and undegraded RNA.
  • the present invention consists of a combination of unique reagents that may be used to purify RNA from a variety of biological materials without the use of hazardous substances such as phenol, and chloroform, or hazardous chaotropic substances such as guanidinium salts, urea, etc.
  • RNA Binding Solution comprises a detergent to make it an RNA Lysing Solution as well.
  • the present invention teaches the use of a unique neutral to high pH RNA Binding Solution Binding Solution.
  • This RNA Binding Solution allows nucleic acids to preferentially bind to a solid support of choice because of the presence of an RNA- complexing salt, preferably an alkali-metal salt in a buffer.
  • the RNA Binding Solution additionally comprises an amphiphillic reagent, such as a detergent, that gives it cell lysing capabilities.
  • This RNA Binding Solution may be referred to as an RNA Lysing Solution.
  • the RNA Lysing Solution lyses the biological material while conferring unique binding properties to the nucleic acids released following lysis such that they preferentially bind to a solid support of choice over other contaminants such as proteins, phospholipids, etc.
  • the RNA Lysing Solution of the present invention achieves this preferential binding by the presence of an RNA-complexing salt such as an alkali-metal salt in a buffer, and optionally an amphiphillic reagent, without the use of hazardous chaotropic substances such as guanidinium salts, urea, etc.
  • the RNA-complexing salt is called as such because it complexes with the charged phosphate backbone of nucleic acids such as RNA.
  • the amphiphillic reagent in the RNA Lysing Solution is preferably a detergent that aids in lysing the biological material.
  • a detergent that aids in lysing the biological material.
  • non-ionic detergents are preferred because they are more soluble in high concentration salt solutions.
  • the RNA Binding Solution and RNA Lysing Solution are buffered to maintain the pH at least about 7 (preferably, at least about 8, more preferably, at least about 8.5, and most preferably, at least about 9).
  • a neutral to basic pH enhances the ability of the nucleic acids, particularly RNA, to bind to the solid support. It is also observed that binding of nucleic acids in the presence of low pH reagents is significantly inhibited.
  • the RNA Binding Solution and RNA Lysing Solution comprise a buffer to adjust the pH as desired.
  • the buffer preferably has a pKa of at least about 8.
  • a preferred buffer is tris(hydroxymethyl)aminomethane (Tris)
  • RNA-complexing salts include alkali-metal salts such as sodium, potassium, lithium, cesium, and rubidium salts.
  • a preferred alkali-metal salt is a lithium salt.
  • Lithium salts used to practice the present invention include, but are not limited to, lithium chloride, and lithium bromide.
  • Preferential binding of RNA to a solid support is enhanced by high concentrations of alkali-metal salts.
  • the alkali-metal salt is at a concentration of between 4 -10 M.
  • the RNA Lysing Solution additionally comprises an amphiphillic reagent.
  • the amphiphillic reagent is a detergent.
  • the detergent may be anionic, cationic, zwitterionic or nonionic but is preferably non-ionic.
  • non-ionic detergents include detergents from the Tween, Triton, Tergitol and Noniodet classes of detergents.
  • the detergents are present at a high concentration of about 10%.
  • the combination of an alkali-metal salt and a detergent, each at the aforementioned high concentrations in a neutral to high pH buffer also serves to neutralize the harmful effects of enzymes such as RNases, generally associated with biological material.
  • the RNA Binding Solution and RNA Lysing Solution may also contain a chelating agent.
  • the invention also incorporates the use of an RNA wash solution to remove impurities such as proteins and phospholipids from the solid support while allowing the nucleic acids to remain bound to the solid support.
  • the RNA wash solution comprises a high concentration of alcohol, and a suitable salt buffered at a neutral pH of between 6-8 M to remove contaminants such as protein, Iipids, etc.
  • RNA Binding Solution or RNA Lysing Solution
  • RNA wash solution in conjunction with an appropriate solid support results in the use of a simple RNA eluting solution such as RNase-free water, or alternately RNase-free water with a non-ionic detergent to elute the RNA from the solid support.
  • RNase-free water or alternately RNase-free water with a non-ionic detergent to elute the RNA from the solid support.
  • the present invention also teaches methods for the isolation of RNA from biological material.
  • the biological material includes, for example, cell or viral suspensions, body fluids and wastes, whole blood, bone marrow, buffy coat, plasma, cultured cells, all suspensions (e.g., bacteria, tissue homogenates), crude or partially purified mixtures of nucleic acids, and environmental samples.
  • the environmental samples include, for example, air, water or soil.
  • the versatility and effectiveness of the RNA Binding Solution or RNA Lysing Solution lends itself to two viable alternative methods for RNA isolation. In the first method, the biological material is contacted with the RNA Binding Solution or RNA Lysing Solution before it is contacted with the solid support.
  • the RNA Lysing Solution is preferentially used. This method serves to lyse the cells and release the nucleic acids including RNA.
  • the RNA Binding Solution or RNA Lysing Solution is added directly to the solid support and allowed to bind to the solid support, thereby eliminating a step, and further simplifying the method.
  • the RNA Binding Solution or RNA Lysing Solution is directly applied to the solid support and then dried on the solid support before contacting the biological material with the treated solid support.
  • Suitable solid supports include cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethersulfone, polyolefin, polyvinylidene fluoride, and combinations thereof.
  • the solid support may be encased or immobilized in a vessel to enable plug-flow or continuous-flow RNA isolation methods.
  • the material of the solid support may be packed so as to create a free-standing solid support such as a membrane, disk, or cylinder that may be immobilized or encased in a suitable vessel.
  • the solid support may be fibrous or particulate to allow optimal contact with the biological material.
  • kits for purifying RNA comprising instruction means for preparing substantially pure and undegraded RNA from a biological sample and one or all of the following: RNA Binding Solution or RNA Lysing Solution, a solid support either untreated or treated with an RNA Binding Solution or RNA Lysing Solution, an RNA wash solution, an RNA eluting solution or any combination thereof.
  • the kit can include a vessel to contain the solid support, vessels to contain substantially pure and undegraded RNA, and combinations thereof.
  • Substantially pure, undegraded RNA is RNA that is suitable for use in subsequent analyses known to those with skill in the art, for example, RT-PCR, in vitro translation, northern blotting, microarray analysis etc.
  • the present invention provides reagents, methods and kits for purifying RNA from biological samples.
  • biological samples include biological material, typically in an aqueous mixture or dried, that contains RNA, including complex biological mixtures of prokaryotic or eukaryotic cells.
  • the methods and kits of the present invention isolate a wide range of RNAs.
  • Candidate RNAs include, but are not limited to, ribosomal RNA, messenger RNA, transfer RNA, and viral RNA, or combinations thereof, all of which can be recovered over a wide molecular weight range.
  • the biological material also contains DNA, carbohydrates, proteins, and Iipids.
  • Biomaterials include, but are not restricted to the following: body fluids such as whole blood, bone marrow, blood spots, blood serum, blood plasma, buffy coat preparations, saliva and cerebrospinal fluid, buccal swabs, cultured cells, cell suspensions of bacteria or tissue homogenates, solid animal tissues such as heart, liver and brain, body waste products, such as feces and urine, environmental samples taken from air, water, sediment or soil, plant tissues, yeasts, bacteria, viruses, mycoplasmas, fungi, protozoa, rickettsia, and other small microbial cells. Lysates, homogenates, or partially purified samples of these biological materials may also be used.
  • the biological material comprises crude or partially purified mixtures of nucleic acids.
  • the reagents, methods and kits of the present invention provide substantially pure and undegraded RNA with relatively little contaminating genomic DNA or other impurities such that the RNA may be used in downstream processes such as RT-PCR and microarray analyses.
  • substantially pure means substantially free of genomic DNA, carbohydrate, protein, lipid impurities, such that the RNA can be used in subsequent analyses known to those with skill in the art such as RT-PCR and microarray analyses.
  • substantially undegraded RNA means nondigested or intact RNA, which can be readily determined by one of skill in the art using standard techniques. That is, the RNA is not damaged by enzymatic, physical or chemical means during the purification methods of the present invention.
  • the reagents, methods and kits of the present invention may be used to purify substantially pure and undegraded RNA over a wide range of biological sources, and life forms, all of which can be recovered over a wide molecular weight range.
  • the substantially pure and undegraded RNA obtained from practicing the invention can also be evaluated for purity, yield, size, reverse transcriptase or other hybridization processes, amplification, hybridization ability, etc.
  • the substantially pure and undegraded RNA is representative of the total RNA found in the biological sample, and is typically a combination of, but not restricted to, mRNA, tRNA, rRNA, and viral RNA.
  • the biological samples include, for example, cell or viral suspensions and pellets thereof, body fluids, and tissue homogenates, etc. If the biological sample consists of cells or viruses, the cells or viruses may be enumerated prior to this step. The enumeration may be conducted using standard cell counting methods such as an electronic cell counter (e.g., CBC5 Coulter Counter, Coulter Corp., Hialeah, FL) or a visual counting chamber (e.g., a hemacytometer, Bright Line, American Optical, Buffalo, NY).
  • the present invention comprises three categories of reagents. These are respectively the RNA Binding Solution (alternatively referred to as the RNA Lysing Solution when it additionally comprises an amphiphillic reagent), the RNA wash solution, and the RNA elution solution.
  • RNA Binding Solution allows nucleic acids to preferentially bind to the solid support of choice.
  • the RNA Lysing Solution enables efficient lysis of the biological sample to release the nucleic acids, and allows them to preferentially bind to the solid support of choice.
  • the RNA Binding Solution comprises the following components: a buffer; an alkali-metal salt; and optionally a chelating agent.
  • the RNA Lysing Solution is comprised of the same elements as the RNA Binding Solution, but additionally comprises an amphiphillic reagent, such as a detergent.
  • RNA Binding Solution and RNA Lysing Solution are unique in that they require no added strong chaotropic substances such as guanidinium salts, urea, etc.
  • Guanidinium salts and urea are strong chaotropic salts that disrupt the structure of water and thus tend to decrease the strength of hydrophobic interactions resulting in a drastic effect on other solute molecules.
  • urea when dissolved in water, disrupts the secondary, tertiary, and quaternary structures of proteins, and subsequently causes dissociation of proteins from RNA.
  • Guanidinium salts and urea dissolve in water through endothermic reactions.
  • Both guanidinium salts and urea are considered to be strongly chaotropic salts as defined by the Hofmeister series, a widely used system that ranks cations and anions according to relative chaotropic strength (F. Hofmeister, On the understanding of the effects of salts, Arch. Exp. Pathol. Pharmakol. (Leipzig) 24 (1888) 247-260). In comparison, neither lithium cation (Li+) nor chloride anion (C1-) are strongly chaotropic in the Hofmeister Series.
  • chloride anion is generally considered a kosmotrope
  • lithium cation exhibits similar solvent effects as sodium cation; hence, LiCl is not a strong chaotrope, and may be considered a kosmotrope.
  • High-concentration Li salts such as LiCl, expose only one of three tryptophanyl residues in RNase A as compared with all three tryptophanyl groups with guanidinium hydrochloride or urea (Ahmad F., J Biol Chem 1983 Sep 25;258 (18):11143-6, Free energy changes in ribonuclease A denaturation: Effect of urea, guanidine hydrochloride, and Lithium Salt.).
  • LiCl induces only local perturbations in protein structure without global effects on secondary, tertiary, or quaternary structure.
  • LiCl is not a chaotrope with broad- range utility for protein unfolding.
  • guanidinium salts are effective at unfolding virtually all proteins.
  • the reaction of lithium salts such as lithium chloride in water is an exothermic reaction. Differences such as these are indicative of the differences between strong chaotropic substances, such as guanidinium salts, and the alkali-metal salts of the present invention and affect their interaction with other components of the RNA Binding Solution and RNA Lysing Solution which consequently affect RNA binding to the solid support.
  • the first component of the RNA Binding Solution or RNA Lysing Solution is a buffer that maintains the pH of said solutions to at least about 7, preferably, at least about 8, more preferably, at least about 8.5, and most preferably, at least about 9.
  • the buffer preferably has a pKa of at least about 8, and is preferably used at a concentration of 10-100 mM.
  • a preferred buffer is Tris buffer.
  • a base may be used to adjust the pH of the RNA Binding Solution or RNA Lysing Solution.
  • the base is one that can raise the pH of said solutions to no less than 7.
  • the base is preferably an alkali-metal hydroxide.
  • Such alkali-metal hydroxides include sodium hydroxide, potassium hydroxide, and lithium hydroxide.
  • the neutral to high pH of the RNA Binding Solution or RNA Lysing Solution enhances the ability of nucleic acids, particularly RNA, to bind to the solid support.
  • the second component of the RNA Binding Solution or RNA Lysing Solution is an RNA-complexing salt that confers unique binding properties to nucleic acids, such as RNA, such that the nucleic acids can preferentially bind to the solid support over other contaminants such as proteins, phosphohpids, etc.
  • an RNA-complexing salt is an alkali-metal salt.
  • Suitable salts include sodium, potassium, and lithium salts.
  • the salts are sodium chloride, potassium chloride, and lithium chloride.
  • the salt is lithium chloride.
  • the salt is present at a high salt concentration of between 4-10 M.
  • the RNA Lysing Solution additionally comprises an amphiphillic reagent.
  • This reagent is comprised of a compound or molecule having a hydrophilic group attached to a hydrophobic functionality such as a hydrocarbon chain and having surfactant properties.
  • the amphiphillic reagent is a detergent.
  • anionic, cationic, and zwitterionic detergents may all be used, RNA isolation is optimally achieved through the use of a non-ionic detergent.
  • Non-ionic detergents lack polar groups and are the mildest of all detergents.
  • the non-ionic detergents are preferably those from the Tween class (Tween-20, Tween-40, Tween-60, Tween-80, etc.), the Triton class (X-100, X-114, XL-80N, etc), Tergitols (XD, TMN-6, etc.) and Noniodets (NP-10, NP-40, etc).
  • the nonionic detergent is used at a concentration of 2 - 20%, more preferably at about 10%.
  • Combinations of non-ionic detergents may also be used.
  • a Tween and a Triton may be used in various ratios, for example, a 1:1 ratio.
  • RNase-free water is used in the
  • a chelating agent may also be used in either solution to prevent degradation of contaminating DNA.
  • the use of a chelating agent prevents DNA polymers from being degraded to smaller fragments which may cause additional contamination problems.
  • the chelating agent is present at a concentration of 1 - 100 mM; more preferably, the chelating agent is present at a concentration of 1-10 mM.
  • the chelating agent is EDTA or CDTA.
  • RNA Binding Solution and RNA Lysing Solution possess significant advantages over reagents used in the prior art.
  • the unique combination of an RNA-complexing salt, and detergent as taught by the present invention each at the aforementioned high concentrations in a neutral to high pH buffer help inactivate enzymes harmful to RNA, such as RNases, without the use of such reagents as phenol, chloroform, and guanidinium salts.
  • both RNA Binding Solution and RNA Lysing Solution confer a high binding property to the nucleic acids such that they tightly bind with the solid support of choice.
  • RNA Wash solution The present invention also teaches an RNA wash solution having a low salt concentration.
  • the RNA Wash solution is used to wash the solid support to which nucleic acids are bound so as to rid it of non-nucleic acid contaminants such as proteins, phosphohpids, etc.
  • the RNA wash solution comprises an alcohol preferably at a concentration greater than 50%; a buffer, and a salt at a low concentration.
  • the RNA wash solution comprises a chelating agent.
  • the low salt concentration means a salt concentration for which downstream desalting steps are unnecessary to prevent the inhibition of downstream processing methods such as RT-PCR.
  • a preferred RNA wash solution is Gentra RNA wash solution (Part. No. S2-0025, Gentra Systems, Inc., Minneapolis, MN).
  • RNA bound to the solid support may be preferentially eluted using n RNA elution solution while leaving the contaminating DNA bound to the solid support.
  • RNAse-free water preferably treated with a substance that inactivates RNases such as diethyl pyrocarbonate (DEPC) may be used.
  • DEPC diethyl pyrocarbonate
  • Other RNA elution solutions known to those skilled in the art may also be used.
  • RNA elution solution is Gentra RNA elution solution (Part. No. S3-0025 Gentra Systems, Inc., Minneapolis, MN).
  • Solid Support A variety of solid supports may be used in the present invention. These include solid supports made of cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethersulfone, polyolefm, polyvinylidene fluoride, and combinations thereof. The size of the solid support suitable for use with the reagents of this invention may vary according to the volume of biological material. For example, when Schleicher and Schuell 903 paper, which has a thickness of 0.5 mm, is used for the solid support, a 3 mm diameter disk will hold about 3 ⁇ l
  • an 8 mm diameter disk will hold about 25 ⁇ l biological material.
  • the thickness and/or diameter of the solid support may increase accordingly.
  • the solid support will be a material that permits the preferential binding of nucleic acids to the solid support in the presence of the aforementioned RNA Lysis Reagent over other biological contaminants.
  • a solid support is comprised of bonded polyester fibers, for example, Filtrona® Filter Media (Lot. No. R-20653).
  • the polyester fibers are fragmented to create smaller particles so as to be accommodated in alternate vessel configurations, or shaped in alternate configurations.
  • One configuration may be an independent freestanding solid support.
  • the shape of the solid support suitable for use with the reagents of this invention may be, for example, a sheet, a precut disk, cylinder, single fiber, or a solid support composed of particulates.
  • the material of the solid support may be packed so as to create a free-standing solid support such as a membrane, disk, or cylinder that may be immobilized or encased in a suitable vessel.
  • the solid support is contained in an appropriate vessel, e.g., a paper form (such as a Guthrie card), a microcentrifuge tube, a spin tube, a 96-well plate, a chamber, or a cartridge.
  • the solid support comprises fibers
  • it may be encased in a suitable vessel so as to pack the fibers appropriately, allow for optimal nucleic acid binding, and the washing away of contaminants such as protein, phosphohpids, etc.
  • the solid support may be pre-treated with the RNA
  • the RNA Lysing Solution is used when the biological material comprises cellular or viral material so as to lyse the biological material and bind the nucleic acids in a single step.
  • the volume of the RNA Binding Solution or RNA Lysing Solution used to treat the solid support is at least one-tenth of the total volume of the solid support. More preferably, the volume of the RNA Binding Solution or RNA Lysing Solution is at least half the total volume of the solid support, and most preferably, the volume of the RNA Binding Solution or RNA Lysing Solution corresponds to the total volume of the solid support.
  • the total volume of the solid support refers to the volume defined by the external boundaries of the solid support.
  • the external boundaries may be dictated by the shape and/or internal boundaries of the vessel containing the solid support.
  • the RNA Lysing Solution may be bound covalently, non-covalently, by being trapped within the interstitial spaces of the solid support, or by being deposited on the material (e.g., fibers, beads, etc.) of the solid support.
  • the RNA Binding Solution or RNA Lysing Solution is allowed to dry on the solid support.
  • the RNA Binding Solution or RNA Lysing Solution may be added directly to the material (e.g., fibers, etc.) used in making the solid support and preferably allowed to dry before it is made into the final user-ready form (e.g., paper, swab, disk, plug, column, etc.).
  • the material e.g., fibers, etc.
  • the final user-ready form e.g., paper, swab, disk, plug, column, etc.
  • the vessel is a cartridge equipped with one or more inlet ports or pierceable septa at the top.
  • the inlet ports are attached to vessels upstream containing the sample or reagents through a connector, such as a female Luer-Lock.
  • One inlet, the sample port is used for the application of the biological sample to the solid support.
  • An optional feature on the sample port is a self-sealing mechanism that seals the sample port after sample has been transferred through it.
  • the second inlet serves as a reagent port.
  • An optional feature on both inlet ports is a protective breakaway seal.
  • the inlet ports, breakaway seals and diffuser may be housed in an optional screw-cap.
  • an optional diffuser At the bottom of the solid support is an optional diffuser with a pore size suitable for the dispersion and passage of cellular debris, proteins and lipid molecules.
  • the diffusers allow for a uniform traversal of biological material across the cross section of the cartridge, and prevent unequal buildup of biological material anywhere above or below the solid support.
  • the outlet of the cartridge comes equipped with a protective cap that fits neatly over the tapered barrel.
  • the purified RNA is collected in a collection tube that consists of a conical tube with a snap cap for easy and contamination-free storage. The entire vessel can be scaled in size depending on the size of the samples to be processed and the yields needed for subsequent analysis.
  • a preferred solid support fashioned out of a Filtrona® Filter Media (Lot. No. R-20653) filter with dimensions of 25.2 mm (circumference) by 3 to 10 mm length which is encased in a suitable tube may either be scaled in size and placed in a larger tube to process larger samples, or alternatively, such filters may be stacked on top or below each other in a tube in order to accommodate varying sample volumes and achieve similar results.
  • the vessel consists of a spin tube designed to hold an insert into which the solid support is packed.
  • the solid support may be cellulose, cellulose acetate, nitrocellulose, nylon, polyester, polyethersulfone, polyolefin, polyvinylidene fluoride, and combinations thereof.
  • the insert consists of a flanged top to hold it in the spin tube and a perforated bottom to allow fluids to pass through while supporting the solid support.
  • a cap tethered to the spin tube may be used to cover the insert.
  • RNA Lysing solution containing non-nucleic acid contaminants for instance, RNA wash solution, or RNA elution solution containing RNA
  • the vessel may be multiple well plates, for example, 6, 12, 24, 48, 96, or 384 well plates where a solid support is packed into each well. The bottom of each well has an exit port through which solutions containing contaminants or purified RNA can pass.
  • RNA Binding Solution or RNA Lysing Solution
  • RNA wash solution or RNA Lysing Solution
  • RNA elution solution results in the isolation of substantially pure, undegraded RNA.
  • the properties of the RNA Binding Solution or RNA Lysing Solution as described above permit preferential binding of the nucleic acids to the solid support, while the RNA Elution solution permits the preferential elution of the RNA from the solid support over that of DNA.
  • the present invention also provides methods for purifying
  • RNA from biological material is contacted with the RNA Binding Solution or RNA Lysing Solution before it is contacted with the solid support.
  • the biological material comprises cellular or viral material
  • the RNA Lysing Solution is used to lyse the biological material and release the RNA before adding it to the solid support.
  • the RNA Lysing Solution prevents the deleterious effects of harmful enzymes such as RNases.
  • the RNA Lysis solution may be successfully used to lyse cultured cells or white blood cells in pellets, or to lyse cells adhering to or collected in culture plates, such as standard 96-well plates.
  • the RNA Lysis solution may be effectively used to grind such tissue chunks into a slurry because of its effective lysing capabilities.
  • the RNA Lysis solution volume may be scaled up or down depending on the cell numbers or tissue size.
  • the lysate may be added directly to the solid support to incubate for at least one minute to allow binding of nucleic acid to the solid support. Preferably, the lysate is allowed to incubate for at least 5 minutes.
  • the RNA Lysing Solution of the present invention may be used to dissociate proteins from the RNA.
  • the RNA Binding Solution or RNA Lysing Solution may be added directly to the solid support, thereby eliminating a step, and further simplifying the method.
  • the RNA Binding Solution or RNA Lysing Solution may be applied to the solid support and then dried on the solid support before contacting the biological material with the treated solid support.
  • a suitable volume of RNA Lysing Solution or RNA Binding Solution is directly added to a solid support placed in a Spin-X basket which is further placed in a 2 ml spin tube.
  • the solid support is heated until dry for at least 12 hours at a temperature of between 40 - 80 °C, after which any excess unbound RNA Lysing Solution or RNA Binding Solution is removed, and is then stored under dessication.
  • the biological material may be directly added to the solid support pre- treated with the RNA Lysing Solution or RNA Binding Solution, and allowed to incubate for at least one minute, preferably at least 5 minutes, until it is suitably lysed and the nucleic acids are released, and bound to the solid support.
  • the biological materials comprise cellular or viral materials
  • direct contact with the RNA Lysing Solution, or contact with the solid support pre-treated with the RNA Lysing Solution causes the cell and nuclear membranes, or viral coats, to solubilize and/or rupture, thereby releasing the nucleic acids as well as other contaminating substances such as proteins, phosphohpids, etc.
  • the released nucleic acids selectively bind to the solid support in the presence of the RNA-complexing salt.
  • the remainder of the biological material is optionally removed by suitable means such as centrifugation, pipetting, pressure, vacuum, or by the combined use of the aforementioned means with an RNA wash solution such that the nucleic acids are left bound to the solid support.
  • the remainder of the non-nucleic acid biological material which includes proteins, phosphohpids, etc. axe removed first by centrifugation, such that the unbound contaminants in the lysate are separated from the solid support.
  • This is followed by one or more wash steps using an adequate volume of a suitable RNA wash solution.
  • Each wash step is followed by a centrifugation step.
  • the number of wash steps is at least two, more preferably the number of wash steps is at least three. The multiple wash steps rid the solid support of substantially all contaminants, and leave behind nucleic acids preferentially bound to the solid support.
  • the bound RNA is preferentially eluted using an adequate amount of an RNA elution solution known to those skilled in the art, leaving the contaminating DNA bound to the solid support.
  • the solid support is then centrifuged, or subject to pressure or vacuum, to release the RNA from the solid support and is collected in a suitable vessel.
  • kits that includes specific protocols, which in combination with the reagents and optionally the solid supports described herein, may be used for purifying RNA from biological materials according to the methods of the invention.
  • the kit includes instruction means.
  • Cultured K562 cells a human lymphoblastoid cell line, were obtained from ATCC (Manassas, NA) and cultured using ATCC recommended medium. The cells were counted using a hemacytometer and sample volumes containing 2 million cells were distributed to 1.7 ml microfuge tubes. The cells were pelleted and centrifuged for 20 seconds at 12000 g, the supernatant fluid removed. These cell pellets were then frozen at -80 °C until use. The cultured cells were thawed on ice and R ⁇ A was purified from the cells by
  • RNA wash solution (Gentra RNA wash solution (Part. No. S2-0025, Gentra Systems, Inc., Minneapolis, MN)) was added to the solid support and centrifuged for 10 seconds at 12,000 x g. The insert containing the solid support was then transferred to a second 2 ml waste collection tube. This wash step was repeated for a total of three consecutive wash steps. However, the third wash was followed by centrifugation for 20 seconds instead of 10 seconds. The insert containing the solid support was then transferred to a clean 2 ml collection tube. To release the RNA from the solid support, a volume of 100 ⁇ l RNA elution solution (Part. No.
  • RNA yields were evaluated for the ability to determine the best type of detergent needed to optimize RNA yields.
  • the following detergents were tested: 1% ammonium lauryl sulfate, 1% dodecyl-trimethylammonium bromide (CTAB), 10% Tween-20 and 10% Triton X-100.
  • CTAB dodecyl-trimethylammonium bromide
  • the detergents were added to a buffer consisting of 45 mM Tris, pH 8.8. A 200 ⁇ l volume of each mixture was added to a solid support (Filtrona® Filter Media Lot #. R- 20619, Filtrona Richmond, Inc. (Richmond, NA)) and dried for 19 hours at 60 °C.
  • RNA elution solution Two million K-562 cells were suspended in phosphate buffered saline (PBS) containing 10 mM EDTA and pipetted onto the solid support.
  • R ⁇ A was purified by washing the solid support three times with 200 ⁇ l R ⁇ A wash solution (Gentra R ⁇ A wash solution (Part. No. S2-0025, Gentra Systems, Inc., Minneapolis, MN)) and eluted with 100 ⁇ l RNA elution solution. In this case, RNase-free water was used as the RNA elution solution. To determine the yield of RNA, a 1 :20 dilution of each sample was prepared in deionized water.
  • a buffered solution such as TE (10 mM Tris, 1 mM EDTA, pH 8.0) may also be used as a diluent.
  • Absorbences at 320 nm (background), 260 nm, and 280 nm were read using a Beckman DU64 Spectrophotometer (Beckman Instruments, Inc., Fullerton, CA), standardized against a blank containing RNA elution solution. The RNA concentration was calculated as
  • RNA Extinction Coefficient x 50 (Dilution Factor); the RNA yield was calculated by multiplying the RNA concentration by the recovered elution volume.
  • An estimate of RNA purity is the absorbance ratio at 260 nm and 280 nm, A 26 o/A 28 o . If the value of this ratio is between 1.8 and 2.1, the sample is considered relatively free of proteins and other contaminants. This ratio is calculated as follows: (A 26 o - A 32 o) / (A 28 o - A 3 o). Both semi-quantitative and qualitative assessments were made by 2% agarose gel electrophoreses.
  • RNA was estimated by examining the intensity of ethidium bromide staining. The quality of RNA was assessed by the presence of ribosomal bands with the 28s fragment roughly twice the intensity of the 18s band. A further indication of quality was the reduction or absence of genomic DNA which was present as a much higher molecular weight band than the RNA bands.
  • RNA sample was mixed with a 1 OX tracking dye and loaded into a 2% agarose gel.
  • the RNA was size separated by
  • RNA contamination was estimated to be less than 10 ng of a possible 600 ng DNA in the 5 ⁇ l sample, or less than 2%.
  • RNA Lysing Solution described in Example 1 at a concentration of 3 xlO 6 cells per ml by adding the RNA Lysing Solution, then gently pipetting up and down five times to form a lysate.
  • the lysate (0J5 ml per well) was aliquoted in to each well of a 96 well flowthrough-plate (hereto referred as the processing plate) of a Generation Capture Plate (Gentra Systems, Minneapolis, MN, Cat. No. 200017) each of which was fitted with a polyester solid support of dimensions 15.39 mm circumference and 15 mm long (Filtrona® Filter Media R-22607, Filtrona Richmond, Richmond, VA).
  • the processing plate was covered with a clean, standard adhesive plate seal, following each reagent addition following centrifugation to prevent contamination.
  • the plate was placed on a Generation Waste plate (Part. No. 200028, Gentra Systems, Minneapolis, MN).
  • the lysate was allowed to incubate with the solid support and the nucleic acids allowed to bind to the solid support for 5 minutes at room temperature, after which the plate was centrifuged at 2000 x g for 3 minutes (Centrifuge Model C412 equipped with an M4 Swing-Out Rotor, catalog no. 11175338; Jouann, Winchester, NA).
  • a volume of 150 ⁇ l R ⁇ A wash solution (Gentra R ⁇ A Wash
  • RNA elution Solution (Part. No. S2-0025, Gentra Systems, Inc., Minneapolis, MN) was added to each well, and the plate was centrifuged twice more as before. After the third wash, the waste plate was replaced with an RNase-free 96-well collection plate. A volume of 100 ⁇ l RNA elution solution (Gentra RNA Elution Solution, Part. No. S3-0025,
  • RNA yield and quality were calculated as described in Example 2. R ⁇ A yields were 8.19 +/- 1.49 ug (17% coefficient of variation).
  • human beta-actin mR ⁇ A was amplified using the 5'- nuclease ("Taqman") assay using an ABI PRISM 7900HT Instrument (Applied Biosystems, Foster City, CA).
  • a single-step reverse-transcription PCR (Taqman EZ RT-PCR Core Reagents, Cat. no. ⁇ 808-0236, Applied Biosystems, Foster City, CA)
  • reaction plate was maintained on ice during the reaction setup.
  • Reactions contained IX EZ RT-PCR Buffer, 3.0 mM manganese acetate, 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM dGTP, 0.6 mM dUTP, IX Human Beta-actin Primer/Probe Mix (VIC) (Cat. no. 4310855, Applied Biosystems, Foster City, CA), 0.2 Units of uracil-N-glycosylase, and 2 Units of rTth DNA polymerase.
  • VOC Human Beta-actin Primer/Probe Mix
  • the plate was sealed with an Optical Adhesive Cover (Cat. No.
  • RNA transcript containing human beta-actin sequences was diluted from 10 11 to 10 copies per reaction for use as a standard curve.
  • the 7900HT Instrument accumulated fluorescence data during the anneal/extend phase of PCR. Data analysis was performed using Sequence Detection Systems Software (SDS version 2.0a23, Applied Biosystems). The standard curve was linear between 1000 and 10 10 copies (R 2 > 0.998).
  • RNA performance in an RT-PCR assay was assessed.
  • RNA was reverse-transcribed in 15 ⁇ l reactions containing 5 ⁇ l of RNA purified following the procedure of Example 1, IX GeneAmp PCR Buffer II (part no. N808-0010, Applied Biosystems, Foster City, CA), 0.1% Igepal CA-630 (Part no. 1-3021, Sigma Chemical, St. Louis, MO), 9.3 mM MgCl 2 (Part no.
  • Reactions were incubated at 25 °C for 10 minutes to allow annealing of random primers, 42 °C for 15 miute., then at 99 °C for 5 minutes to inactivate reverse transcriptase.
  • PCR mix was added, and amplification carried out for 5 cycles of 92 °C for 5 seconds, 64 °C for 30 seconds, 72 °C for 1 minute and 25 cycles of 94 °C for 5 seconds, 64 °C for 30 seconds, 72 °C for 1 minute, followed by a final extension at 72 °C for 15 minutes.
  • Reactions contained 20 mM Tris-sulfate, pH 9.0, 20 mM ammonium sulfate, 0.1% Igepal CA-630, 300 nM each primer BA-F 5'- GCCAACCGCGAGAAGATGAC ; BA- R: 5'-CCGTCACCGGAGTCCATCAC synthesized by Keystone Division of BioSource, Foster City, CA., and 2.5 Units Taq D ⁇ A polymerase (Promega, Madison, WI). These PCR primers generate an amplicon of 134 base pairs from beta-actin mR ⁇ A.
  • Reaction products were analyzed by electrophoresis on 2% agarose gels (100V 1 h) containing 0.5 ug/ml ethidium bromide. Bands were visualized by UV transillumination. Products of the expected size were observed.
  • larger amplicons were readily amplified from isolated R ⁇ A using other primer sets. If R ⁇ A were substantially degraded, the larger amplicons would not be detected using standard gel electrophoreses methods.
  • a set of PCR primers from tryptophanyl tR ⁇ A synthetase mR ⁇ A (F: 5'- CCAGGGAACCCAGCACCTAC ; R: 5'-AAAGCCACAGGCGATGATGTC each synthesized by Keystone, Foster City, CA) were used successfully to amplify t a 492- base pair fragment from 10 samples of total RNA isolated by the present invention.
  • Guanidinium salts are among the most potent known inactivators of RNases. Thus, it was of interest to discover if potent chaotropes such as guanidinium isothiocyanate (GITC) and guanidinium hydrochloride could either substitute for lithium chloride or increase RNA yields using the reagents in the method of the present invention.
  • GITC guanidinium isothiocyanate
  • guanidinium hydrochloride could either substitute for lithium chloride or increase RNA yields using the reagents in the method of the present invention.
  • RNA Lysing Solution Three sets of experiments were conducted. The experimental conditions are as follows: (1) solid supports pre-treated with GITC; (2) cells pre-lysed in GITC, and then added to the solid support; and (3) the addition of chaotropes to the RNA Lysing Solution of Example 1.
  • the solid support of Example 1 Frtrona® Filter Media Lot No. R-20653, Filtrona Richmond, Inc. (Richmond, VA)
  • the solid supports were coated with RNA Lysing Solution or a GTIC lysing solution (Buffer RLT, Qiagen, Valencia, CA) by pipeting 200 ⁇ l of the solution onto the filter, then drying at 68 °C for 18 hours.
  • Treated solid supports were tested in duplicate for their ability to purify RNA from K562 cells following the method in Example 2. Agarose gel electrophoresis of the purified RNA showed that the yield of RNA using GITC lysing solution (Buffer RLT, Qiagen, Valencia, CA) was less than 10% of the yield of RNA observed when the RNA Lysing Solution of the present invention was used to bind to the filter as described in Example 2.
  • the second set of experiments attempted to evaluate the ability of GITC to facilitate binding of RNA to the solid support.
  • K562 cells were lysed in Buffer RLT (Qiagen, Valencia, CA), then applied to an untreated filter. Binding in the presence of Buffer RLT gave significantly lower yields, less than 50% of RNA using RNA Lysing Solution as described in Example 1.
  • RNA Lysing Solution of the invention as described in Example 1, to which was added 4 M guanidinium isothiocyanate, 6M guanidinium hydrochloride, or 8.3M urea was used to purify RNA according to the method described in Example 1. It was determined that the pH of each of the aforementioned solutions were 8.8. 8.8, and 8.6 respectively. RNA yields obtained using the urea-LiCl Lysing Solution were about 35% of the RNA yields using the RNA Lysing Solution of Example 1.
  • Example 6 Effect of Low pH on RNA Purification Using a Solid Support RNases are rapidly and efficiently inactivated at low pH. Hence, it was of interest to determine if the present method could be enhanced by the use of a low pH RNA Lysing Solution.
  • RNA Lysis Solutions were prepared, one at low pH (pH 4.6) and a second at high pH (pH 8.8) according to Example 2 of the present invention, except that the 45 mM Tris pH 8.8 buffer was replaced by 45 mM Citrate buffer pH 4.6.
  • a 300 ⁇ l volume of each RNA Lysis Solution was added to a solid support (Filtrona Lot # R 20653, Filtrona Richmond, Inc. (Richmond, VA)) and dried as described as in Example 2. Following the RNA purification method from Example 2 the quantities of recovered RNA were determined by UV spectrophotometry.
  • RNA purified using pH 4.6 RNA Lysis Solution was 3.60 ug (standard deviation was 0.86 with 4 replicates) while the average yield using pH 8.8 RNA Lysis Solution was 11.40 ug (standard deviation was 0.32 with four replicates) .
  • the results showed that reducing the pH of the Lysis Solution significantly reduced the yield and purity of the resulting RNA.
  • RNA preparations be substantially free of DNA to give consistent and reliable results.
  • Genomic DNA contamination is a problem with many current RNA purification technologies. It was of interest to assess the genomic DNA content of purified RNA purified by the reagents and method of the current invention. Two assays were employed to assess genomic DNA content: real time quantitative PCR and agarose gel electrophoresis. In the first assay, DNA content was estimated from RNA purified in a 96 well format as described in Example 3. Genomic DNA content of the purified RNA was estimated with a quantitative assay using a Taqman RNase P assay.. The single-copy human RNase P gene was
  • RNA was purified from 12 samples using the column method described in Example 1 and from 12 samples using the commercially available kit (RNAeasy, Qiagen, Cat. No. 74103 (Valencia, CA)).
  • RNase P values in ng DNA were expressed as a percentage of total nucleic acid (calculated from A 26 o - A 32 o using 40 ⁇ g/ml as the conversion, assuming mostly RNA).
  • the invention represents a significant improvement over existing technology.
  • genomic DNA was estimated from agarose gel electrophoresis of purified RNA.
  • genomic DNA is clearly visible as a band migrating more slowly than the 28s rRNA band.
  • RNA purified by the present invention was observed to contain significantly less genomic DNA than the aforementioned kit.
  • no genomic DNA band was visible. This data shows that the reagents and methods of the present invention yield RNA of significantly higher purity than some currently available commercial kits.
  • Total RNA was purified from 10 million K562 cells using the method of the invention according to the procedure described in Example 1 , using an RNA elution
  • the resulting microarray images demonstrated strong signal at both the Cy3 and Cy5 excitation wavelengths with very low background fluorescence.
  • GenePixTM Pro 3.0 analysis software (Axon Instruments, Inc., Foster City, CA) was used to determine signal-to-noise ratios. Ratios were calculated for 24 grids with 16 spots per grid, where each spot was compared to the perimeter region immediately surrounding it. Negative spots were not included in the analysis. A positive hybridization signal is defined by the manufacturer as being greater than 3 fold over background.
  • the mean signal-to-noise ratios for both Cy3 and Cy5 excitation wavelengths were well above that level, at 7.015 and 10.678 respectively, indicating very low background fluorescence from high quality RNA.
  • RNA samples were analyzed using an Agilent 2100 bioAnalyzer (Agilent Technologies, Palo Alto, CA). This system may be used to assess the size and quality of the major ribosomal RNA bands generating an electropherogram and calculating the ratio between the 28s and 18s peak areas. Generally, two resolvable peaks with ratios greater than 1.5 indicate that the RNA sample is undegraded.
  • RNA from a total of 50 x IO 6 K562 cells was purified according to the protocols described in Example 1 with the exception that the RNA lysis volumes were 500, 750 and 1000 ⁇ l respectively, and RNA elution volumes were 20, 60, and 100 ⁇ l.
  • RNA LabChip® (Agilent Technologies, Palo Alto, CA) prepared in a reagent supplied by the manufacturer and according to the manufacturer's instructions. Following electrophoresis, the resulting electropherogram was examined. All samples showed two distinct 28s and 18s peaks. The average 28s to 18s ratio was 2.46, with a range of 1.89 to 3.53 for all samples. The ratios were thus all greater than 1.5, indicating that the method of the present invention generated substantially undegraded RNA.
  • Treated filters Feiltrona® Filter Media (Lot. No. R-20653)) were prepared by pipetting 0.2 ml of RNA Lysing Solution onto each filter in a Spin-X carrier tube, then heating at 68°C for 12-18 hours in a laboratory oven. Plasma (0.2 to 0.4 ml) was applied to the treated filter, and RNA was allowed to bind for 5 minutes at room temperature. The filter was washed as described in Example 1.
  • RNA Lysing Solution was mixed with the human plasma at ratios of between two to six, and the entire sample was applied to the solid support with exogenous nucleic acid (10-30 ⁇ g of human total cellular RNA per isolation obtained from K562 cells). The solid support was then washed and eluted, following the method described in Example 1. The addition of the exogenous carrier RNA was found to improve yields significantly, by at least 50% over conditions in which no carrier RNA was used.
  • HCV specific RT-PCR was performed. Primers specific to a 241 base target in the 5 '-untranslated (5 -UTR) region of HCV were used. Reverse transcription was performed in 30 ⁇ l reactions
  • the plate was heated as follows in an ABI PRISM 7900HT Instrument (Applied Biosystems, Foster City, CA): 50°C for 2 minutes; 95°C for 10 minutes; 94°C for 5 seconds, and 60°C for 1 minute for 50 cycles. Data were collected during the anneal/extend phase of PCR and analyzed using Sequence Detection System software (SDS) version 2.0. Amplification was observed using RNA purified from plasma RNA using both treated and untreated filters.
  • SDS Sequence Detection System software
  • CBC-7 Hematology Controls R&D Systems, Minneapolis, MN.
  • a volume of 200 ul was removed and combined with 600 ul RBC Lysis Solution (Gentra Systems, Inc., Minneapolis, MN) in a 1.7 ml microfuge tube.
  • the white cells were pelleted by centrifuging at 12,000 x g for 20 seconds.
  • the supernatant fraction containing the lysed red cells was removed and the pellet was rinsed with 300 ul RBC Lysis Solution to further remove contaminants.
  • the white blood cells were suspended in RNA Lysis Solution and the RNA purified according to Example 1.
  • Beta globin transcripts were amplified using a one step reverse transcriptase PCR amplification kit (rTth Amplification Kit Cat. No. n808-0098 PE Biosystems, Foster City, CA) according to the manufacturer's instructions.
  • the primer sequences were F 5' TAG CCA CAC CAG CCA CCA CTT TCT-3' and R 5' CCT GGC TCA CCT GGA CAA CCT CAA-3'.
  • the purified RNA was amplified using the cycling conditions of 60°C for 30 minutes, 94 °C for 3 minutes followed by 30 cycles of 94 °C for 1 minute, 70 °C for 1 minute, 72 °C for 1 minute and then completed by incubating for 7 minutes at 72 °C. To determine whether the RNA isolated using the present invention was of sufficient purity to be reverse transcribed into cDNA and then

Abstract

L'invention concerne des réactifs, des procédés et des nécessaires destinés à la purification de l'ARN des matériaux biologiques.
PCT/US2001/032073 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn WO2003033739A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002211719A AU2002211719B2 (en) 2001-10-12 2001-10-12 Compositions and methods for using a solid support to purify RNA
EP01979794A EP1438426A1 (fr) 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn
CA002463317A CA2463317A1 (fr) 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn
JP2003536461A JP3979996B2 (ja) 2001-10-12 2001-10-12 固体支持体を使用してｒｎａを精製するための組成物および方法
PCT/US2001/032073 WO2003033739A1 (fr) 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/032073 WO2003033739A1 (fr) 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn

Publications (1)

Publication Number Publication Date
WO2003033739A1 true WO2003033739A1 (fr) 2003-04-24

Family

ID=21742909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032073 WO2003033739A1 (fr) 2001-10-12 2001-10-12 Compositions et procedes utilises en tant que support solide afin de purifier de l'arn

Country Status (5)

Country Link
EP (1) EP1438426A1 (fr)
JP (1) JP3979996B2 (fr)
AU (1) AU2002211719B2 (fr)
CA (1) CA2463317A1 (fr)
WO (1) WO2003033739A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382677A1 (fr) * 2002-07-19 2004-01-21 Fuji Photo Film Co., Ltd. Méthode de séparation et de purification d'acides nucléiques
EP1442045A2 (fr) * 2001-11-06 2004-08-04 Cortex Biochem Inc. Isolement et purification d'acides nucleiques
EP1448799A2 (fr) * 2001-11-28 2004-08-25 Applera Corporation Compositions et procedes d'isolation selective d'acides nucleiques
WO2004094635A2 (fr) * 2003-04-16 2004-11-04 Gentra Systems, Inc. Compositions et procedes d'utilisation d'un support solide pour purifier de l'arn
WO2005007895A1 (fr) * 2003-07-11 2005-01-27 Applera Corporation Methodes et kits permettant d'obtenir des acides nucleiques a partir d'echantillons biologiques
WO2005058933A1 (fr) 2003-12-16 2005-06-30 Gentra Systems, Inc. Preparations et methodes de denaturation de proteines
WO2005093065A1 (fr) * 2004-03-16 2005-10-06 Roche Diagnostics Gmbh Methode amelioree d'isolement d'acides nucleiques
WO2007050327A3 (fr) * 2005-10-21 2007-08-09 Gentra Systems Inc Appareil compact, compositions et procedes pour la purification d'acides nucleiques
EP1920054A1 (fr) * 2005-08-30 2008-05-14 FUJIFILM Corporation Procede pour separer et purifier l 'arn
WO2009040444A1 (fr) * 2007-09-28 2009-04-02 Mole Genetics As Procédé d'isolement d'arn
US7776616B2 (en) 1997-09-17 2010-08-17 Qiagen North American Holdings, Inc. Apparatuses and methods for isolating nucleic acid
AU2005305012B2 (en) * 2004-11-05 2012-01-12 Qiagen North American Holdings, Inc. Compositions and methods for purifying nucleic acids from stabilization reagents
US8598338B2 (en) 2001-10-12 2013-12-03 Qiagen North American Holdings, Inc. Compositions and methods for using a solid support to purify DNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US10435735B2 (en) 2014-03-07 2019-10-08 Dna Genotek Inc. Composition and method for stabilizing nucleic acids in biological samples
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US11002646B2 (en) 2011-06-19 2021-05-11 DNA Genotek, Inc. Devices, solutions and methods for sample collection
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11572581B2 (en) 2002-06-07 2023-02-07 DNA Genotek, Inc. Compositions and methods for obtaining nucleic acids from sputum

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010183A (en) * 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
WO1995034569A1 (fr) * 1994-06-14 1995-12-21 Invitek Gmbh Procede universel d'isolement et de purification d'acides nucleiques a partir de quantites extremement reduites de differents materiaux de depart fortement contamines
US5728822A (en) * 1993-02-01 1998-03-17 Qiagen N.V. Quaternary amine surfactants and methods of using same in isolation of RNA
US5939259A (en) * 1997-04-09 1999-08-17 Schleicher & Schuell, Inc. Methods and devices for collecting and storing clinical samples for genetic analysis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010183A (en) * 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
US5728822A (en) * 1993-02-01 1998-03-17 Qiagen N.V. Quaternary amine surfactants and methods of using same in isolation of RNA
WO1995034569A1 (fr) * 1994-06-14 1995-12-21 Invitek Gmbh Procede universel d'isolement et de purification d'acides nucleiques a partir de quantites extremement reduites de differents materiaux de depart fortement contamines
US5939259A (en) * 1997-04-09 1999-08-17 Schleicher & Schuell, Inc. Methods and devices for collecting and storing clinical samples for genetic analysis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUGOS R C ET AL.: "RNA Isolation from Plant Tissues Recalcitrant to Extraction in Guanidine", BIOTECHNIQUES, vol. 19, no. 5, November 1995 (1995-11-01), pages 734 - 737, XP001055648 *
DAHLE C E AND MACFARLANE D E: "Isolation of RNA from Cells in Culture Using Catrimox-14 Cationic Surfactant", BIOTECHNIQUES, vol. 15, no. 6, December 1993 (1993-12-01), pages 1102 - 1105, XP001055650 *
WITCHEL H J ET AL.: "Milligram Quantity Preparation of RNA from a Marine Invertebrate with a High Fluid Content", BIOTECHNIQUES, vol. 21, no. 5, December 1996 (1996-12-01), pages 1024 - 1026, XP001026264 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776616B2 (en) 1997-09-17 2010-08-17 Qiagen North American Holdings, Inc. Apparatuses and methods for isolating nucleic acid
US7767804B2 (en) 2001-10-12 2010-08-03 Qiagen North American Holdings, Inc. Compositions and methods for using a solid support to purify RNA
US8598338B2 (en) 2001-10-12 2013-12-03 Qiagen North American Holdings, Inc. Compositions and methods for using a solid support to purify DNA
US7148343B2 (en) 2001-10-12 2006-12-12 Gentra Systems, Inc. Compositions and methods for using a solid support to purify RNA
EP1442045A4 (fr) * 2001-11-06 2006-09-27 Cortex Biochem Inc Isolement et purification d'acides nucleiques
US7264927B2 (en) 2001-11-06 2007-09-04 Cortex Biochem, Inc. Isolation and purification of nucleic acids
EP1442045A2 (fr) * 2001-11-06 2004-08-04 Cortex Biochem Inc. Isolement et purification d'acides nucleiques
US8507198B2 (en) 2001-11-28 2013-08-13 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US7537898B2 (en) 2001-11-28 2009-05-26 Applied Biosystems, Llc Compositions and methods of selective nucleic acid isolation
US7208271B2 (en) 2001-11-28 2007-04-24 Applera Corporation Compositions and methods of selective nucleic acid isolation
EP1448799A2 (fr) * 2001-11-28 2004-08-25 Applera Corporation Compositions et procedes d'isolation selective d'acides nucleiques
US8865405B2 (en) 2001-11-28 2014-10-21 Applied Biosystems Llc Compositions and methods of selective nucleic acid isolation
EP1448799A4 (fr) * 2001-11-28 2006-03-08 Applera Corp Compositions et procedes d'isolation selective d'acides nucleiques
US11572581B2 (en) 2002-06-07 2023-02-07 DNA Genotek, Inc. Compositions and methods for obtaining nucleic acids from sputum
EP1382677A1 (fr) * 2002-07-19 2004-01-21 Fuji Photo Film Co., Ltd. Méthode de séparation et de purification d'acides nucléiques
US7252939B2 (en) 2002-07-19 2007-08-07 Fujifilm Corporation Method for separating and purifying a nucleic acid
WO2004094635A3 (fr) * 2003-04-16 2004-12-16 Gentra Systems Inc Compositions et procedes d'utilisation d'un support solide pour purifier de l'arn
WO2004094635A2 (fr) * 2003-04-16 2004-11-04 Gentra Systems, Inc. Compositions et procedes d'utilisation d'un support solide pour purifier de l'arn
WO2005007895A1 (fr) * 2003-07-11 2005-01-27 Applera Corporation Methodes et kits permettant d'obtenir des acides nucleiques a partir d'echantillons biologiques
EP1694692A4 (fr) * 2003-12-16 2008-07-23 Qiagen North American Holdings Preparations et methodes de denaturation de proteines
US7115719B2 (en) 2003-12-16 2006-10-03 Gentra Systems, Inc. Formulations and methods for denaturing proteins
WO2005058933A1 (fr) 2003-12-16 2005-06-30 Gentra Systems, Inc. Preparations et methodes de denaturation de proteines
EP1694692A1 (fr) * 2003-12-16 2006-08-30 Gentra Systems, Inc. Preparations et methodes de denaturation de proteines
WO2005093065A1 (fr) * 2004-03-16 2005-10-06 Roche Diagnostics Gmbh Methode amelioree d'isolement d'acides nucleiques
US10947527B2 (en) 2004-11-05 2021-03-16 Qiagen North American Holdings, Inc Compositions and methods for purifying nucleic acids from stabilization reagents
AU2005305012B2 (en) * 2004-11-05 2012-01-12 Qiagen North American Holdings, Inc. Compositions and methods for purifying nucleic acids from stabilization reagents
AU2005305012C1 (en) * 2004-11-05 2012-07-19 Qiagen North American Holdings, Inc. Compositions and methods for purifying nucleic acids from stabilization reagents
EP1920054A4 (fr) * 2005-08-30 2009-08-26 Fujifilm Corp Procede pour separer et purifier l 'arn
US7884201B2 (en) 2005-08-30 2011-02-08 Fujifilm Corporation Method for separating and purifying RNA
EP1920054A1 (fr) * 2005-08-30 2008-05-14 FUJIFILM Corporation Procede pour separer et purifier l 'arn
WO2007050327A3 (fr) * 2005-10-21 2007-08-09 Gentra Systems Inc Appareil compact, compositions et procedes pour la purification d'acides nucleiques
GB2466419A (en) * 2007-09-28 2010-06-23 Mole Genetics As RNA isolation method
GB2466419B (en) * 2007-09-28 2011-04-13 Mole Genetics As RNA isolation method
WO2009040444A1 (fr) * 2007-09-28 2009-04-02 Mole Genetics As Procédé d'isolement d'arn
US11549870B2 (en) 2011-06-19 2023-01-10 DNA Genotek, Inc. Cell preserving solution
US11002646B2 (en) 2011-06-19 2021-05-11 DNA Genotek, Inc. Devices, solutions and methods for sample collection
US11536632B2 (en) 2011-06-19 2022-12-27 DNA Genotek, Inc. Biological collection system
US11592368B2 (en) 2011-06-19 2023-02-28 DNA Genotek, Inc. Method for collecting and preserving a biological sample
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US11692189B2 (en) 2013-03-14 2023-07-04 Translate Bio, Inc. Methods for purification of messenger RNA
US11820977B2 (en) 2013-03-14 2023-11-21 Translate Bio, Inc. Methods for purification of messenger RNA
US11198899B2 (en) 2014-03-07 2021-12-14 Dna Genotek Inc. Composition and method for stabilizing nucleic acids in biological samples
US10435735B2 (en) 2014-03-07 2019-10-08 Dna Genotek Inc. Composition and method for stabilizing nucleic acids in biological samples
US11059841B2 (en) 2014-04-25 2021-07-13 Translate Bio, Inc. Methods for purification of messenger RNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US11884692B2 (en) 2014-04-25 2024-01-30 Translate Bio, Inc. Methods for purification of messenger RNA
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA

Also Published As

Publication number Publication date
CA2463317A1 (fr) 2003-04-24
JP3979996B2 (ja) 2007-09-19
JP2005505305A (ja) 2005-02-24
EP1438426A1 (fr) 2004-07-21
AU2002211719B2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
US7893228B2 (en) Compositions and methods for using a solid support to purify RNA
US7148343B2 (en) Compositions and methods for using a solid support to purify RNA
AU2002211719B2 (en) Compositions and methods for using a solid support to purify RNA
AU2002211719A1 (en) Compositions and methods for using a solid support to purify RNA
CA2319775C (fr) Compositions et procedes d'utilisation d'une matrice lytique pour isoler un adn
EP1694692A1 (fr) Preparations et methodes de denaturation de proteines
US7790865B1 (en) Eluting reagents, methods and kits for isolating DNA
CA2319691C (fr) Reactifs d'elution, procedes et trousses permettant d'isoler un adn
CA2319665C (fr) Procedes permettant d'isoler, d'amplifier et de caracteriser un adn
EP2290099B1 (fr) Procédés permettant d'isoler, d'amplifier et de caractériser un ADN
AU2004233035B2 (en) Compositions and methods for using a solid support to purify RNA
AU2007200429B2 (en) Compositions and methods for using a lysing matrix for isolating DNA
AU2017268667A1 (en) Processes for isolating, amplifying and characterizing DNA
AU2007200486A1 (en) Processes for isolating, amplifying and characterizing DNA
AU2013219151A1 (en) Processes for isolating, amplifying and chacterizing DNA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002211719

Country of ref document: AU

Ref document number: 2463317

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003536461

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001979794

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001979794

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002211719

Country of ref document: AU